Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Single Dose Study to Evaluate the Safety and Tolerability of ER-100 in Optic Neuropathies [Open Angle Glaucoma (OAG) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)]

Next Previous
Trial Profile

A Phase 1 Single Dose Study to Evaluate the Safety and Tolerability of ER-100 in Optic Neuropathies [Open Angle Glaucoma (OAG) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)]

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ER 100 (Primary)
  • Indications Glaucoma; Ischaemic optic neuropathy; Open-angle glaucoma; Optic nerve disorders
  • Focus Adverse reactions; First in man
  • Sponsors Life Biosciences

Most Recent Events

  • 09 Mar 2026 Status changed from not yet recruiting to recruiting.
  • 20 Dec 2025 Status changed from planning to not yet recruiting.
  • 22 Jul 2025 According to Life Biosciences media release, company plans to enter the clinic in the first quarter of 2026 for indications including glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top